For those who didn't catch the Tweed

New Post Public Reply Private Reply Replies (0) Message Board
ChicagoInvestor
For those who didn't catch the Tweed news…

REVENUES

The Company reported initial sales of $188,736, coming from the last two months of the quarter.

OPERATING EXPENSES

Operating expenses for the quarter ended June 30, 2014 was $1,134,427 as compared to $1,194,591 for the quarter ended March 31, 2014. These expenses have been incurred as the Company hired employees in the areas of operations, production and administration, pursued and invested in specific educational and outreach initiatives as well as the required government permits, engaged expertise in developing its business and production strategies, and incurred costs of implementing and expanding the growing operations.

Share-based compensation expenses of $147,797 in Q2 and $306,223 for the six months ended June 30, 2014 relate to the expense associated with the stock options granted to employees and consultants during fiscal 2013 and the two quarters of 2014.

Amortization of intangible assets for the first quarter ending June 30, 2014 amounted to $5,755, and for the six months ended June 20 2014, to $8,222. These relate to the amortization of the cost associated with the acquisition of the tweed.com domain name, which is being amortized over a five-year period.

Amortization of property, plant and equipment for the first quarter ending June 30, 2014 amounted to $43,734. Assets in leasehold construction in progress totaling $5,309,951 have been transferred to property, plant and equipment on June 30, 2014 as construction was complete and the leasehold was available for use. Amortization on these assets will commence July 1, 2014.

NET LOSS

The net loss for the quarter ending June 30, 2014 was $1,160,317 and for the six month period ended June 30, 2014 was $3,778,197.

[….]

The build-out program, production process, and active medical education program have provided some insight to the market and potential offering. Tweed believes the facilities constructed and licensed by the end of 2014 will have the production potential of approximately 7,000,000 grams on an annualized basis. The price range for the product is forecast to be an average of $7 per gram in 2015. The target margin at the 2014 run rate of production is estimated to be approximately seventy percent. Tweed is on schedule to have an on-site lab operational by early Q4, which is expected to reduce time to market, lower testing costs, and facilitate further research and development.

The Board recognizes the opportunity for Tweed to continue to accelerate. Tweed is now a multi-license, multi-site company that has established a platform that could produce significant growth. Chuck Rifici has made key contributions to date as the CEO and Co-Founder. Having led Tweed through its startup phase, Chuck is stepping down as CEO to help the company recruit a CEO with the skills and experience to take Tweed to the next level of expected high-volume and rapid growth in this aggressive market segment.

Effective immediately the Chairman and Co-Founder, Bruce Linton will act as the interim CEO. The Board looks forward to Chuck's continued involvement on the Board.


Not enough production capability yet for positive net income, CEO leaving, reports of low quality medicine, looks like some may move positions from Tweed to CEN. GLTA.

Source: http://www.newswire.ca/en/story/1403658/tweed...des-update

Creative Edge Nutrition Inc. (FITX) Stock Research Links

FITX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 310

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 607

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 386

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 513

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 731

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle

Updated Category News Views 98

A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 385

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 518

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 137

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 332

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
icles